<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078218</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/27</org_study_id>
    <nct_id>NCT03078218</nct_id>
  </id_info>
  <brief_title>Health-economic Impact of Pulse Oximetry Systematic Screening of Critical Congenital Heart Disease in Asymptomatic Newborns</brief_title>
  <acronym>OXYNAT</acronym>
  <official_title>Health-economic Impact of Pulse Oximetry Systematic Screening of Critical Congenital Heart Disease in Asymptomatic Newborns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persistant hypoxemia in the newborn confers, even isolated, an abnormal clinical situation,
      that needs to be addressed for an adequate diagnosis and an optimal treatment.

      If during the first hours of life, hypoxemia is frequent and often transient, beyond that, it
      is necessary to search the various etiological conditions such as a critical congenital heart
      disease (CCHD) or a non cardiac affection (sepsis, anemia, respiratory disease).

      Newborn pulse oximetry screening identifies babies with critical congenital heart disease
      (CCHD) based on the rational that they frequently have a degree of hypoxemia that may be
      clinically undetectable. CCHDs are life-threatening forms of congenital heart disease (CHD)
      occuring in 2-3/1000 live births but accounting for 3%-7.5% of infant deaths.

      Early detection is beneficial because of acute collapse, if not resulting in death, is
      associated with a worse surgical and neurodevelopmental outcome.

      Currently, screening for CCHD involves antenatal ultrasound scanning and post-natal physical
      examination. Although antenatal detection rates have improved over recent years and can be as
      high as 70%-80% in some centers, this is not consistent. Indeed, in &quot;Nouvelle Aquitaine&quot;
      overall &lt;50% of CCHDs are detected before birth. In addition, up to a third of infants with
      CCHD may be missed on post-natal examination. Pulse oximetry screening can help to close the
      &quot;diagnostic gap' that is, increase the detection of babies who slip through the current
      screening net.

      Several large European studies and a subsequent meta-analysis have shown that pulse oximetry
      screening is a highly specific (99.9%) and moderately sensitive (76.5%) test which increases
      CCHD detection rates. The high specificity results in a low false-positive rate 0.05% to
      0.5%. But those babies with a Positive Test, if they may not have CCHD, they may be diagnosed
      with other causes of hypoxemia (congenital pneumonia, sepsis, persistent pulmonary
      hypertension,...). As with CCHD, delayed recognition of these conditions can result in
      postnatal collapse and significant morbidity and mortality. It is also more useful to
      consider these conditions as secondary targets of screening and to remember they constitute
      30%-70% of false positives. In 2011, the US Health and Human Services Secretary recommended
      that pulse oximetry screening for CCHD be added to the Recommended Uniform Screening Panel.
      In Europe, implementation is advanced in such countries as North European Countries, and
      Switzerland. There isn't yet any European guidance. In France, the implementation is limited
      to local and transient experiments. The feasibility, usefulness and cost-effectiveness of
      routine pulse oximetry screening have not been evaluated so far. The French setting has two
      specificities : 1/ the antenatal detection rate is considered to be rather high. 2/ in
      contrast to a lot of other European countries, early discharge from the maternity ward before
      48 hours of life is not common, decreasing the risk of discharging a baby with undiagnosed
      CCHD, but not saving babies from collapse.

      - The Investigators hypothesis is that routine pulse oximetry screening in asymptomatic
      newborns would allow to reduce the incidence of complications related to CCHDs as well as
      those related to non cardiac pathologies for a reasonable cost for the French Health Care
      System.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Multicenter controlled before and after study conducted in Nouvelle Aquitaine, including types 1, 2 and 3 maternity wards.
The BEFORE period will be strictly observational in order to assess the current screening strategy as it is conducted in real life.
The AFTER period will be consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards as the BEFORE period.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental cost-effectiveness ratio</measure>
    <time_frame>Up to 12 month of each period</time_frame>
    <description>Difference of mean costs between the two strategies divided by the difference in the number of complications between the two strategies. Complications of interest are: acute respiratory distress, acute cardio-circulatory distress (collapse, acidosis, shock, multivisceral failure), and death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental cost per life saved</measure>
    <time_frame>Up to 12 month of each period</time_frame>
    <description>Difference of mean costs between the two strategies divided by the difference in the number of saved lives between the two strategies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net monetary benefit for the French Health System of generalizing the pulse oximetry screening</measure>
    <time_frame>Up to 12 month of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of pulse oximetry screening for critical congenital heart defects in France.</measure>
    <time_frame>The duration of a pulse oximetry examination</time_frame>
    <description>Costs will be calculated in the perspective of the French Health System. The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performances of pulse oximetry for the diagnostic of CCHD and non-cardiac disease</measure>
    <time_frame>Up to 12 month of the after period</time_frame>
    <description>sensibility, specificity, positive predictive value, negative predictive value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34704</enrollment>
  <condition>Critical Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Before period group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Strictly observational in order to assess the current screening strategy as it is conducted in real life</description>
  </arm_group>
  <arm_group>
    <arm_group_label>After period group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pulse oximetry</intervention_name>
    <description>The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.</description>
    <arm_group_label>After period group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        BEFORE Period: newborns

          -  aged at birth superior or equal to 35 weeks of gestation (≥ 35+ 0 days weeks of
             gestation)

          -  borned in metropolitan France in involved maternity wards.

          -  Asymptomatic before the screening (no respiratory signs, neither collapse or cardiac
             arrest).

        AFTER Period: newborns

          -  aged at birth superior or equal to 35 weeks of gestation (≥ 35+ 0 days weeks of
             gestation)

          -  borned in metropolitan France in involved maternity wards.

          -  Asymptomatic before the screening (no respiratory signs, neither collapse or cardiac
             arrest).

          -  With consent done by the 2 parents.

          -  Parents covered with the French National health insurance

        Exclusion Criteria:

          -  Newborns with a prenatally diagnosed congenital cyanotic malformation or any other
             cyanotic affection.

          -  Newborns with a postnatal pre-screening diagnosed congenital cyanotic malformation or
             any other cyanotic affection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie THOMAS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine BENARD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie THOMAS, MD</last_name>
    <phone>(0)5.57.65.61.10</phone>
    <phone_ext>+33</phone_ext>
    <email>julie.thomas@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Severine LE PUIL</last_name>
    <email>severine.lepuil@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Agen</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire BRIENNON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claire BRIENNON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Esquirol - Saint Hilaire</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques ELHARRAR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques ELHARRAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Angoulême</name>
      <address>
        <city>Angouleme</city>
        <zip>16959</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mélie SARREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mélie SARREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de la Haute Gironde</name>
      <address>
        <city>Blaye</city>
        <zip>33394</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe FILET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe FILET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33077</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leïla PLANTARD-CHEKROUN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leïla PLANTARD-CHEKROUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Brive</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <zip>19100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane HARANT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane HARANT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Jean Villar</name>
      <address>
        <city>Bruges</city>
        <zip>33523</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier JOURDAIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier JOURDAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Châtellerault</name>
      <address>
        <city>Chatellerault</city>
        <zip>86106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence COMPAIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florence COMPAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Dax</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric ROUSSEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric ROUSSEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Guéret</name>
      <address>
        <city>Guéret</city>
        <zip>23000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mustapha LAYADI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mustapha LAYADI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maternité Pernelle d'Aufrédy CH de La Rochelle - Ré - Aunis</name>
      <address>
        <city>La rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Arcachon</name>
      <address>
        <city>La Teste de buch</city>
        <zip>33260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcelin KIBELO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcelin KIBELO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-René NELSON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-René NELSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe BROSSET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe BROSSET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Emailleurs</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric SELLAM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric SELLAM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Rive droite</name>
      <address>
        <city>Lormont</city>
        <zip>33310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Béatrice BAUDOIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Béatrice BAUDOIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Marmande</name>
      <address>
        <city>Marmande</city>
        <zip>47207</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Roger SASSIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Roger SASSIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence PRIQUELER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence PRIQUELER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Niort</name>
      <address>
        <city>Niort</city>
        <zip>79000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile CAMARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>ODILE CAMARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Périgueux</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre DARWICHE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre DARWICHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie THOMAS, MD</last_name>
      <email>julie.thomas@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Séverine LE PUIL</last_name>
      <email>severine.lepuil@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric DUMAS-DE-LA-ROQUE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie THOMAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabrice PIERRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Fabrice PIERRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Rochefort</name>
      <address>
        <city>Rochefort</city>
        <zip>17301</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne LISKA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne LISKA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saint Junien</name>
      <address>
        <city>Saint Junien</city>
        <zip>87200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne CONSTANTY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne CONSTANTY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Saintes</name>
      <address>
        <city>Saintes</city>
        <zip>17100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra ROBERT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandra ROBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Soyaux</name>
      <address>
        <city>Soyaux</city>
        <zip>16800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bénédicte TESSIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bénédicte TESSIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maison de Santé Protestante de Bordeaux Bagatelle</name>
      <address>
        <city>Talence</city>
        <zip>33401</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie ROQUAND-WAGNER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emilie ROQUAND-WAGNER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulse oximetry</keyword>
  <keyword>Asymptomatic newborns</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

